Denosumab: +21.7% 10-Year BMD Gain & Rebound Fracture Risk

Theme

Denosumab Delivers Compelling Decade-Long Bone Density Gains and Fracture Risk Reduction, but Demands Strategic Exit Protocols to Prevent Rebound Bone Loss

Source
Source: Scientific review of systematic reviews, meta-analyses, and randomized controlled trials (including the FREEDOM, VICTOR, DATA, ROSALIA, and FRAME studies) evaluating the efficacy and safety of denosumab in patients with postmenopausal osteoporosis.
+21.7%
Lumbar Spine BMD Gain

Cumulative increase over 10 years of continuous therapy in the FREEDOM extension trial, demonstrating linear efficacy without a therapeutic plateau.

Study Architecture

Population Postmenopausal women with osteoporosis/low BMD; additional subsets include men and CKD patients.
Primary Arms Denosumab vs. Placebo, Bisphosphonates, Anabolics (Romosozumab, Teriparatide), and SERMs.
Duration 12–24 months in transition studies; up to 10 years of continuous therapy.
Endpoints BMD % change, fracture incidence, AEs/SAEs, ONJ, AFF, and rebound effects post-cessation.

Vertebral Fractures

72% risk reduction compared to placebo (RR=0.28). Annual incidence remained exceptionally low (0.90%–1.86%) over 10 years.

12-Mo Lumbar BMD

Yields greater BMD increases than bisphosphonates, but trails the initial rapid gains of anabolic agents.

Discontinuation Risks

Rapid Rebound Bone Loss Stopping Denosumab triggers a swift rebound in bone turnover markers, leading to rapid BMD loss and a significantly elevated risk of multiple vertebral fractures.
Long-Term Safety Profile (10 Years):
  • ONJ: 13 total cases
  • AFF: 2 total cases
  • Extremely low absolute event rates during continuous therapy.

Clinical Recommendation & Transition Protocol

Denosumab is highly recommended as a robust second-line therapy for patients intolerant to bisphosphonates, or as a first-line option for those at very high fracture risk. However, denosumab should never be abruptly discontinued without a transition plan. To mitigate the well-documented rebound effect, clinicians must sequentially transition patients to an alternative antiresorptive agent (typically a bisphosphonate) accompanied by intensive monitoring for at least 12 months post-cessation.

AbbreviationsQuick
AEs: adverse events, AFF: atypical femoral fractures, BMD / МПКТ: bone mineral density, CI / ДИ: confidence interval, CKD / ХБП: chronic kidney disease, CoE: certainty of evidence, CTX-1: C-terminal telopeptide of type I collagen, FN: femoral neck, LS: lumbar spine, ONJ: osteonecrosis of the jaw, P1NP: procollagen type 1 N-terminal propeptide, PD: pharmacodynamics, PK: pharmacokinetics, QALY: quality-adjusted life-year, RANKL: receptor activator of nuclear factor kappaB ligand, RCT / РКИ: randomized controlled trial, RR / ОР: relative risk, SAEs: serious adverse events, SERM: selective estrogen receptor modulator, TH: total hip.
Bibliography8
  1. Ayers Chelsea et al. "Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians." Annals of internal medicine 176 (2023): 182-195. PMID: 36592455.
  2. Händel Mina Nicole et al. "Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials." BMJ (Clinical research ed.) 381 (2023): e068033. PMID: 37130601.
  3. Bone Henry G et al. "10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension." The lancet. Diabetes & endocrinology 5 (2017): 513-523. PMID: 28546097.
  4. Qaseem Amir et al. "Pharmacologic Treatment of Primary Osteoporosis or Low Bone Mass to Prevent Fractures in Adults: A Living Clinical Guideline From the American College of Physicians." Annals of internal medicine 176 (2023): 224-238. PMID: 36592456.
  5. Wang W-Y et al. "Drug efficacy and safety of denosumab, teriparatide, zoledronic acid, and ibandronic acid for the treatment of postmenopausal osteoporosis: a network meta-analysis of randomized controlled trials." European review for medical and pharmacological sciences 27 (2023): 8253-8268. PMID: 37750653.
  6. Kobayakawa Tomonori et al. "Verification of efficacy and safety of ibandronate or denosumab for postmenopausal osteoporosis after 12-month treatment with romosozumab as sequential therapy: The prospective VICTOR study." Bone 162 (2022): 116480. PMID: 35787482.
  7. Sølling AnneSophie, Tsourdi Elena, Harsløf Torben, Langdahl BenteL. "Denosumab Discontinuation." Current osteoporosis reports (2022). PMID: 36564572.
  8. Jeka Sławomir et al. "Equivalence trial of proposed denosumab biosimilar GP2411 and reference denosumab in postmenopausal osteoporosis: the ROSALIA study." Journal of bone and mineral research 39 (2023): 202-210. PMID: 38477751.
👀 View Mode